St-Georges Eco-Mining Announces Amendment to the Letter of Intent Between its Subsidary ZEU CRYPTO NETWORKS INC. and TIANDE
Momentum Public Relations
Press Release: February 7 2018
– St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF)
(FSE: 85G1) announced today that its previously announced letter of intent dated January 12,
2018 relating to an asset acquisition between SX’s subsidiary, ZeU Crypto Networks Inc. and
Qingdao Tiande Blockchain Information Technology Co. Ltd. has been amended. The general
terms of the LOI, which referred to Qingdao Tiande Technologies Limited instead of Qingdao, were
previously announced by press release dated January 14, 2018.
ZeU, Qingdao and Beijing Tiande Technologies Limited. (“Beijing” and collectively with
Qingdao, “Tiande”) entered into the amendment to the LOI (the “Amendment”), which has
extended the date by which the parties will conclude the execution of a definitive agreement on
or around February 19, 2018 or such later date as may be mutually agreed upon by the
parties. The proposed acquisition is subject to a number of terms and conditions, including but
not limited to, the completion of a concurrent financing not less than $10,000,000 and up to
$30,000,000 that can be done in tranches and the receipt of all necessary regulatory, corporate
and third party approvals.
The Amendment also revised the consideration structure, such that the proposed Acquisition will
now be settled through the issuance of 75,000,000 common shares of ZeU (each a “Share”) and
75,000,000 Share purchase warrants (each a “Warrant”) on Closing and an additional
75,000,000 Shares after the filing for registration of the 20th patent derived from the intellectual
property and patent application acquired from Tiande. Each Warrant will be exercisable at a
price of CND$1.00 for a period of three (3) years following the date ZeU completes a transaction
pursuant to which its Shares will either be listed on a recognized stock exchange in North
America, or will be exchanged for common shares of a reporting issuer listed on a recognized
stock exchange in North America.
Frank Dumas, President & CEO of St-Georges and of ZeU Crypto Networks commented: “The
Acquisition required an extensive due diligence effort and has its own particular challenges. We
are happy with the current progress and we can now see the finish line ahead of us. Some
elements that are ‘sensitive’ to third party sovereign entities increased the expected workload.
The current proposal should allow Tiande to operate in China as an exclusive partner to ZeU,
giving ZeU the exclusive ownership and right to develop and commercialize the technologies
outside of China and would also call for the establishment of a “Canadian Intellectual Property
(IP) Container” and a “Chinese Intellectual Property (IP) Container” allowing for a “Chinese
Source Code” to be exclusively used in China without any possibility for North American
oversight.”
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS, PRESIDENT & CEO
About St-Georges
St-Georges is developing new technologies to solve the some of the most common
environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active
mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial
minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the
Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the
symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange
under the symbol 85G1.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility
for the adequacy or the accuracy of the contents of this release.
Compliance and medias contact: 514.295.9878
- Published in St-Georges Eco-Mining, Uncategorized
Auxico Announces Results of Innovative Mettalurgical Testing
Momentum Public Relations
Press Release: February 6 2018
Auxico Resources Canada Inc. (CSE:AUAG) is pleased to announce results from innovative metallurgical testing conducted on its gold/silver properties located in the state of Sinaloa, Mexico.
Series of tests that have been conducted on gravity concentrates from the Campanillas and Aguamas properties have resulted in the recoveries of over 98% of gold and 87% of silver within the same leach. These tests have been conducted over the last year using a mix of acids composed of sulfuric acid and thioria. The extraction (less than one hour) is accelerated by the use of ultrasound technology and the process uses no external heat or pressure.
SAMPLE | Feed material % Au | Recovery % Au | Feed material % Ag | Recovery % Ag |
Aguamas | 0.01 | 98.00 | 0.08 | 88.76 |
Campanillas | 0.05 | 98.00 | 0.05 | 87.47 |
These results are highly encouraging, as the process will significantly reduce both capital and operating expenditures, while having a much smaller environmental footprint.
Qualified Person
This news release was reviewed and approved by Joel Scodnick, P.Geo., an independent consultant to Auxico, in his capacity as a Qualified Person, as defined by National Instrument 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS
« signed »
Mark Billings
President, Auxico Resources Canada Inc.
mb@auxicoresources.com
Cell: +1 514 296 1641
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) in a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Mexico. The Company has a 100% interest in the Zamora Silver-Gold Property in Sinaloa, Mexico. Auxico will continue to identify and potentially acquire additional property interests and conduct exploration and evaluation of these properties to assess their potential.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in Auxico Resources, Mining
Arctic Star Discovers New Kimberlite
Momentum Public Relations
Press Release: February 6 2018
Arctic Star Exploration Corp (TSXV: ADD) (OTCQB: ASDZF) (FSE: 82A1) (WKN: A2DFY5) (the “Company” or “Arctic Star”) is pleased to announce the discovery of a new kimberlite on its 100% owned Timantti Diamond Project in Finland. Further investigation of a drill core sample from a previous explorer held in the core archive of the GTK (the Finnish Geological Survey) at Loppi, Finland, has confirmed the kimberlite discovery.
Finnish kimberlite expert Dr Hugh O’Brien of the GTK has undertaken petrographic and mineralogical examinations to confirm the new discovery. The new kimberlite is located approximately 230m west of the diamond bearing Black Wolf Kimberlite. There’s no record of this drill core being announced to the public.
In June 2005, previous explorer Karhu Mining Oy, drilled a geophysical magnetic target. Hole D476 intersected a meter of kimberlite in an inclined (-45°) hole located within a zone of extensive alteration and brecciation. Dr O’Brien has conducted a detailed petrographic and mineralogical examination of the core from hole D476 and has confirmed that the kimberlite is “A micaceous Group II kimberlite importantly containing abundant indicator minerals including olivine macrocrysts 5mm in diameter.”
Dr O’Brien further stated “This kimberlite is very similar in texture and mineralogy to the rocks that form the diamond-bearing Wolf kimberlites. The existence of this kimberlite close to the Wolf kimberlites strongly indicates that the area is part of a kimberlite field and that the prognosis for additional discoveries in the area is quite high.“
Roy Spencer stated “As has been previously expressed by myself and supported now by kimberlite expert Dr Hugh O’Brien, kimberlites typically occur in fields or clusters and this exciting discovery 230 metersaway from the Wolves strongly supports the thesis that we are looking at such a field here north of Kuusamo. With only a single intersection we do not yet know what form this kimberlite will take but we suspect that the body has not been investigated any further previously, and are glad to add another kimberlite to the pack.”
ABOUT ARCTIC STAR: The Company owns 100% of the recently acquired Timantti Diamond Project including a 243 Ha Exploration Permit and a 95,700 Ha Exploration Reservation near the township of Kuusamo, in Finland. The project is located approximately 450km NW of the operating Grib Diamond Mine in Russia. Arctic is commencing its exploration in Finland on the Timantti Project, where two diamondiferous kimberlites may represent the first finds in a large kimberlite field. The Company also controls diamond exploration properties in Nunavut (Stein), the NWT (Diagras and Redemption) and a rare metals project in BC (Cap). Arctic Star has a highly experienced diamond exploration team previously responsible for numerous world class diamond discoveries.
ON BEHALF OF THE BOARD OF DIRECTORS OF
ARCTIC STAR EXPLORATION CORP.
“Scott Eldridge”
Scott Eldridge, President & CEO
+1 (604) 722-5381
scott@arcticstar.ca
“Patrick Power”
Patrick Power, Executive Chairman
+1 (604) 218-8772
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements: Certain statements in this press release are forward-looking statements within the meaning of applicable securities laws. Forward-looking statements in this press release include that the Timantti Project transaction is a pre-eminent opportunity.
- Published in Arctic Star Exploration
ATW grants new option shares
Momentum Public Relations
Press Release: February 5, 2018
ATW Tech (“AtmanCo” or the “Company”) (TSX-V:ATW) announces that a total of 2 387 000 share purchase options have been granted to officers, employees and consultants of the Company as well as members of the board of directors, pursuant to the terms of its share option plan (the “Plan”). These options are exercisable at $0.13 per share and expire on February 4, 2023. The Plan provides that options may be exercised on a cumulative basis over a period of four years from the date they are granted, as to one-fourth every year.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech (‘AtmanCo’) (TSX-V:ATW) is a leader in information technology, owner of several web platforms including VoxTel, Québec Rencontres, VuduMobile, Atman and Bloomed. VoxTel offers various interactive communication and landline and mobile carrier billing phone solutions. Quebec Rencontres is a web and mobile social network application catered to building serious and sustainable relationships. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Atman and its APIs enable companies to optimize their human capital. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors, which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH (AtmanCo) Michel Guay Founder, president and CEO Tel.: 514.935.5959 ext. 301 mguay@atwtech.com www.atwtech.com |
Simon Bédard, CA, CPA, CFA, MBA CFO Tel. : 514.935.5959 ext. 304 sbedard@atmanco.com |
Relevium Improves Financial Position and Provides Updates on Warrants Exercises and Share for Services Agreement
Momentum Public Relations
Press Release: February 5, 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to report improvements on its financial position, provide an update on warrants exercised to date and on shares issued to its corporate secretary on a share for services agreement.
Improved Financial Position and Warrants Exercises to-date
The company has received warrant and options exercises and issued 13,591,361 shares at a weighted average price of $0.15, resulting in total cash proceeds of $2,008,704. Aurelio Useche, CEO stated: “Combined with the debt conversion announced on December 12, 2017, the company has significantly improved its financial position. We want to thank our loyal shareholders for their support and loyalty as we pursue our objectives in 2018.”
Shares Issued to Corporate Secretary per Share for Services Agreement
The company also announced it has issued 27,300 shares on Friday February 2, 2018 at a deemed price of $0.183146 per share to the Company’s Corporate Secretary, Mr. David A. Johnson, pursuant to a shares-for-services agreement disclosed in a company press release dated October 20, 2017. The shares are subject to a four month hold period. Pricing was determined using the VWAP on the close of February 2, 2018.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Relevium Technologies Inc.
Edward Ierfino
Investor Relations
+1(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Momentum Public Relations
Press Release: February 5, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.
Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug. This trial is expected to be a landmark study, enrolling a total of 946 subjects, evaluating the therapeutic benefits of a cannabinoid prescription drug in improving quality of life and treating pain in terminal cancer patients.
“This is an especially significant and noteworthy milestone for the lead candidate in our product pipeline,” said Bernard Fortier, Tetra’s CEO, “as it positions Tetra to potentially be the first company with a Health Canada approved, cannabinoid-based drug on the market aimed at treating breakthrough pain in cancer patients. The advanced cancer pain market is a $2.4B market1; this is a significant and important opportunity for the Company as our drug PPP001 has the potential to help reduce the reliance on opioids for the management of severe pain.”
The first and main recruitment center of the trial will be in Montreal at Santé Cannabis, Québec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.
The PPP001 Phase 3 trial will evaluate the effects of Tetra’s smokable cannabinoid-based drug made from natural dried cannabis. Tetra previously entered into a supply agreement with Aphria Inc., to use Aphria’s unique blend of dried medical cannabis in its PPP001 clinical trial. Aphria owns an 8.5% stake in Tetra.
As part of the clinical trial, Tetra will also collect the pharmaco-economics evidence required from insurers in order to support the reimbursement of the first cannabis prescription drug. “Today, most private insurance plans do not cover cannabis treatment, nor is public reimbursement available, making this therapeutic option costly for patients. It is very important for us to bring a new therapeutic option for patients in the form of an approved prescription drug and to take action in order to have it reimbursed for patients” commented Bernard Fortier, CEO.
The trial aims to demonstrate that PPP001 eases suffering and facilitates a more serene experience of living and dying in terminal cancer patients. If conclusive, Tetra will submit a filing for a Drug Identification Number (DIN) to Health Canada in 2019, thus providing a new noninvasive treatment to relieve pain for cancer patient. With this approval, Tetra expects to be on time with its previously announced schedule with the development of PPP001, culminating in a potential launch in Canada by Q1, 2020 and in the US by Q3, 2020.
Dr Guy Chamberland, Tetra’s Chief Scientific Officer (CSO) explained that: “The development of PPP001 for patients with advanced cancer is an important commitment for Tetra, given that cancer patients suffer from severe pain which is often accompanied by depression and insomnia. Medical cannabis has been shown to help patients beyond the immediate benefit of pain relief.”
“With the expertise of Santé Cannabis, we expect to demonstrate the clinical benefits of PPP001 on the quality of life of advanced cancer patients. It’s important to note that our clinical program will also address the potential of PPP001 to reduce the reliance on opioids for management of severe pain. We expect that, once it is approved as a drug under prescription, PPP001 will be included over time ahead of opioids treatment for those patients with terminal cancer pain. The Company will continue to maintain a transparent and direct line of communication with Health Canada and the U.S. FDA to ensure that we address the issues required for drug approval. PPP001 is about patients first, ” added Dr. Guy Chamberland.
Tetra worked with Santé Cannabis physicians to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients and have focused the clinical development on a first indication in patients with advanced cancer. The Phase III clinical trial will be performed by the medical team of Santé Cannabis.
“Throughout my clinical experience assessing and following more than 600 medical cannabis patients, cannabis inhalation remains a critical option to provide rapid relief from a wide variety of symptoms associated with advanced cancer, ” said Dr. Antonio Vigano, Principal Investigator of the trial and Research Director of Santé Cannabis. “We will rigorously assess the safety, efficacy and tolerability of PPP001 to support the population of cancer patients by bringing an important therapeutic tool to the same standard of prescription drugs It is great to be celebrating World Cancer Day 2018 with the first large scale clinical study to prove that medical cannabis can ease the suffering and improve quality of life of many cancer patients, particularly when they most need it.”
About Cancer Pain:
In the USA, 1,5 million patients suffer from cancer pain2. Pain is one of the most frightening of all cancer symptoms for patients and their families3. According to statistics published by the American Cancer Society in 20024, 50% to 70% of people with cancer experience some degree of pain, with a quarter of them actually dying in pain. Without adequate relief of their pain, their quality of life is negatively impacted. Furthermore, the incidence of pain in advanced stages of invasive cancer approaches 80% and it is 90% in patients with bone metastases5.
- https://decisionresourcesgroup.com/report/141466-biopharma-cancer-pain-2015
- Melnikova I. Pain market 2010 ;, doi:10.1038/nrd3226
- Winslow M, Seymour J, Clark D. 2005. Stories of cancer pain: a historical perspective. J Pain Symptom Manage, 29:22-31.
- American Cancer Society. 2002. Cancer facts and figures 2002
- Pharo GH, Zhou L. 2005. Pharmacologic Management of Cancer Pain. JAOA, 105:S21-28.
About PPP001:
PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9,5% THC and 2,5% CBD.
About Aphria:
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556
- Published in Marijuana, Medical Marijuana, Tetra Bio Pharma
Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry
Momentum Public Relations
Press Release: February 2, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments and Biomimicry.
The conference showcases animal adaptations to extreme polar environments, and how these adaptations have inspired commercial technology. Dr. Deliencourt-Godefroy will present on February 3rd at 11:00 AM CET, on the glycoproteins that were discovered in Arctic fishes and her advancement of the technology in human cell preservation. Her talk can be streamed live at:
https://cite-sciences.ubicast.tv/permalink/l1253c0f84c1fnr2u6ni/iframe/
NB: the conference is held in French.
About Milieux Polaires et Biomimétisme and Poles Actions
The yearly symposium is organized by Poles Actions and is dedicated to polar biomimicry.
The association of Poles Actions is intended to promote the knowledge and the protection of Arctic and Antarctic ecosystems through awareness, education and support for research in polar and subpolar regions. It acts as a nonpartisan, objective and scientifically credible channel of communication, based on the activities and experience of its members and external stakeholders. It organizes educational interventions, exhibitions, conferences and scientific expeditions to help publicize and protect these fragile ecosystems. For more information, visit: http://www.ourspolaire.org/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
Crystal Lake shareholders approve all matters at AGM
Momentum Public Relations
Press Release: February 1, 2018
Crystal Lake Mining Corp. has released the results of its annual general meeting of shareholders which was held on Jan. 31, 2018.
Richard Savage, John Meekison, Alphonse Ruggiero and Wally Boguski were re-elected to the board. All motions were approved by shareholders and the company’s shareholder rights plan was renewed. Mr. Savage will continue as chief executive officer and Mr. Ruggiero will continue as chief financial officer.
The company thanks shareholders for their continued support and look forward to an exciting year ahead.
About the company
Crystal Lake is a mineral exploration/development company with a focus on creating value through the exploration and development of the company’s Ontario mineral properties.
We seek Safe Harbor.
- Published in Crystal Lake Mining